Positron vice president of pharmaceuticals Scott Stiffler said from inception, their Crown Point facility was designed specifically to facilitate Positron’s growth plans into radiopharmaceuticals.
"The NRC license allows us to bring this facility to its fully functional and operational stage, and to immediately move into the development, production and sales of radiochemical compounds, with a planned near-term expansion into radiopharmaceuticals for oncology and cardiology," Stiffler said.
"A radioactive material handling license at this facility is a critical step that allows Positron to expand its business through the development and manufacturing of new technologies, medical devices and radiopharmaceuticals, thereby further solidifying our position in the marketplace."
